Physician profile
David G Ray
NPI 1053314526
$13,786.95
in general payments reported to CMS, 2019-2025
33 companies · $2,117 in 2025
The $2,117 reported for 2025 was more than what 79% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $966 · 2021: $2,905 · 2022: $2,106 · 2023: $1,584 · 2024: $3,275 · 2025: $2,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,644 · Travel and Lodging: $778 · Consulting Fee: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,643.55 |
| Travel and Lodging | $777.81 |
| Consulting Fee | $555.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,544.62 | 2020-2025 | Intracept, Na, Avista Mri |
| Nevro Corp. | $2,499.79 | 2019-2024 | Senza |
| Nalu Medical, INC. | $2,138.86 | 2021-2025 | Nalu Neurostimulation System |
| Abbott Laboratories | $1,792.80 | 2019-2025 | Proclaim, Eterna |
| Vertos Medical, INC. | $896.96 | 2021-2024 | Mild Device Kit |
| Medtronic, INC. | $658.27 | 2022-2025 | Inceptiv, Intellis Adaptivestim |
| Medtronic USA, INC. | $604.87 | 2019 | |
| Collegium Pharmaceutical, INC. | $249.13 | 2022-2024 | Xtampza |
| Saluda Medical Americas, INC. | $200.96 | 2024 | Evoke |
| Stryker Corporation | $179.54 | 2024 | Mild Device Kit |
| Biotronik Nro, INC. | $162.99 | 2024-2025 | Prospera |
| Ibsa Pharma INC. | $116.88 | 2023-2025 | Tirosint, Licart, Tirosint |
| Relievant Medsystems, INC. | $112.67 | 2021 | |
| Axonics, INC. | $84.32 | 2020-2021 | |
| Spr Therapeutics, INC | $82.42 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $80.26 | 2024-2025 | Roxybond |
| Vertex Pharmaceuticals Incorporated | $58.16 | 2025 | |
| Scilex Pharmaceuticals INC. | $38.14 | 2022-2023 | Ztlido |
| Electronic Waveform Lab, INC. | $34.24 | 2022-2025 | |
| Depuy Synthes Sales INC. | $32.10 | 2022-2024 | Orthovisc |
| Fidia Pharma USA INC. | $30.06 | 2023 | Hymovis |
| Biohaven Pharmaceuticals, INC. | $27.96 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.00 | 2025 | Relistor |
| Zoll Respicardia, INC. | $19.68 | 2023 | Remede System |
| Otto Bock Healthcare LP | $17.38 | 2021 | |
| Lilly USA, LLC | $15.89 | 2021 | |
| Abbvie INC. | $15.06 | 2023 | |
| Tonix Medicines, INC. | $14.74 | 2025 | Tonmya |
| Grt US Holding, INC. | $13.92 | 2020 | |
| Painteq LLC | $13.38 | 2023 | Painteq |
| Mdd US Operations, LLC | $11.74 | 2019 | |
| Pfizer INC. | $11.32 | 2019 | |
| Kerecis Limited | $6.84 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.